STOCK TITAN

Aptevo Therapeutics (APVO) director reports vesting and conversion of 400 RSUs

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. director Barbara Lopez Kunz reported the vesting and conversion of 400 Restricted Stock Units (RSUs) into 400 shares of common stock on August 6, 2026. The RSUs convert into common stock on a one-for-one basis. These 400 RSUs were part of a grant of 7,200 RSUs (400 post-split) awarded on August 6, 2025, which vested on the first anniversary of the grant date.

Positive

  • None.

Negative

  • None.
Insider Kunz Barbara Lopez
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit F1, F2 400 $0.00 $0.00
Exercise Common Stock F1 400 -- --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 400 shares (Direct)
Footnotes (2)
  1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
  2. F2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
RSUs converted 400 RSUs RSUs converted into common stock on August 6, 2026
Common shares received 400 shares Shares of common stock issued upon RSU conversion
Original RSU grant 7,200 RSUs (400 post-split) Granted on August 6, 2025, vesting on first anniversary
Post-transaction common holdings 400 shares Direct common stock holdings reported after the transaction
Restricted Stock Unit financial
"Restricted Stock Units ("RSUs") convert into common stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
one-for-one basis financial
"RSUs convert into common stock ... on a one-for-one basis"
post-split financial
"the reporting person was granted 7,200 (400 post-split) RSUs"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Aptevo Therapeutics (APVO) report for Barbara Lopez Kunz?

Barbara Lopez Kunz reported the vesting and conversion of 400 RSUs into 400 shares of common stock on August 6, 2026, reflecting an equity compensation event rather than an open-market purchase or sale.

How many Aptevo Therapeutics (APVO) RSUs vested and converted in this Form 4?

A total of 400 Restricted Stock Units vested and converted into 400 shares of common stock. The RSUs convert on a one-for-one basis, meaning each RSU became one share upon vesting.

What was the original RSU grant disclosed in the Aptevo (APVO) Form 4?

On August 6, 2025, the reporting person was granted 7,200 RSUs, noted as 400 post-split RSUs, which were scheduled to vest on the first anniversary of the grant date, leading to this 2026 vesting event.

Did the Aptevo (APVO) Form 4 report any open-market buy or sell transactions?

No open-market buys or sells were reported. The filing shows an exercise/conversion of 400 RSUs into common stock, an equity compensation vesting event without a reported market trade price.

How many Aptevo (APVO) common shares does the director hold after the RSU conversion?

Following the RSU conversion, the reported direct holdings from this transaction are 400 shares of common stock. This figure reflects the shares resulting from the 400 RSUs that vested and converted.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kunz Barbara Lopez

(Last)(First)(Middle)
2401 4TH AVENUE
SUITE 1050

(Street)
SEATTLE WASHINGTON 98121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/06/2026M400A(1)400D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)08/06/2026M400 (2) (2)Common Stock400$00D
Explanation of Responses:
1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
/s/ SoYoung Kwon, Attorney-in-Fact08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)